EVALUATION AND MANAGEMENT OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION

Federal Bureau of Prisons
Clinical Guidance

AUGUST 2018

Federal Bureau of Prisons (BOP) Clinical Guidance is made available to the public for informational purposes only. The BOP does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp.
WHAT’S NEW IN BOP GUIDANCE REGARDING HCV INFECTION?

The current version of this guidance contains the following major revisions:

- **HCV Screening:** The BOP recommends opt-out voluntary testing of all inmates for HCV infection, regardless of sentencing status, including new intakes and those already in population who have not been previously tested.

- **HCV Treatment:** All sentenced inmates are eligible for consideration of treatment for chronic HCV infection. BOP Priority Criteria have been retained as a guide for deciding whom to treat first.

- **Priority Level 2 Criteria:** Birth cohort 1945–1965 was added to Priority Level 2. Fifty percent of HCV-related deaths occur in this population.

- **Hepatitis C Treatment Algorithm:** The Non-formulary Request Worksheet has been updated to include the five parameters (albumin, bilirubin, INR, ascites, hepatic encephalopathy) of the Child-Turcotte-Pugh (CTP) score.

The major changes included in the January 2018 update were as follows:

- Two new combination direct-acting antiviral (DAA) medications have been FDA-approved for the treatment of chronic hepatitis C virus (HCV) infection and are now included in Section 6, Recommended Treatment Regimens:
  - Glecaprevir/pibrentasvir (Mavyret™) and
  - Sofosbuvir/velpatasvir/voxilaprevir (Vosevi®).

- Recommended HCV treatment regimens have been updated to reflect the current guidance from the American Association for the Study of Liver Diseases (AASLD).

- The APRI cutoff for treatment Priority Level 2 has been lowered to ≥ 0.7.

- The appendices containing drug information tables are no longer included in this guidance. In light of the rapidly changing HCV treatment landscape, providers are now referred to manufacturer’s prescribing information, Facts and Comparisons (available in BEMR), and other validated resources for the most up-to-date information on individual HCV drugs.
TABLE OF CONTENTS

1. PURPOSE AND OVERVIEW .......................................................................................... 1

2. SCREENING FOR HCV INFECTION .................................................................... 2
   Inmate History and Patient Education .................................................................. 2
   Screening Criteria ................................................................................................. 2
   Screening Method .................................................................................................. 3
   Refusal of Testing .................................................................................................. 3

3. INITIAL EVALUATION OF ANTI-HCV POSITIVE INMATES. . ............................ 3
   Baseline Evaluation ............................................................................................... 4

4. ASSESS FOR HEPATIC CIRRHOSIS AND DECOMPENSATION ....................... 5
   Assessing for Hepatic Fibrosis and Cirrhosis ....................................................... 6
   Assessing Hepatic Compensate ......................................................................... 7
   TABLE 1: Using CTP Scores to Assess Hepatic Compensation ......................... 7
   Additional Interventions for Inmates with Cirrhosis ............................................ 7

5. BOP PRIORITY CRITERIA FOR HCV TREATMENT ......................................... 8
   Priority Level 1: High Priority for Treatment * .................................................. 8
   Priority Level 2: Intermediate Priority for Treatment * ...................................... 8
   Priority Level 3: Low Priority for Treatment * .................................................. 9
   Other Criteria for Treatment .............................................................................. 9

6. RECOMMENDED TREATMENT REGIMENS ...................................................... 10
   Direct Acting Antiviral Medications (DAAs) ....................................................... 10
   Preferred Treatment Regimens .......................................................................... 14
   Potential Drug Interactions .................................................................................. 15
   Regimens Not Recommended .............................................................................. 15

7. MONITORING ........................................................................................................ 15
   Pretreatment Assessment .................................................................................... 15
   On-Treatment Monitoring ................................................................................... 16
   Post-Treatment Monitoring .................................................................................. 18
   Ongoing Monitoring ............................................................................................ 18

8. SPECIAL CONSIDERATIONS .............................................................................. 19
   HCV Infection with More Than One Genotype .................................................. 19
   HBV Coinfection .................................................................................................. 19
   HIV Coinfection .................................................................................................. 19
   Decompensated Cirrhosis .................................................................................... 20
   TABLE 2: HCV Treatment Recommendations for Decompensated Cirrhosis .... 21
   Liver Transplant Recipients ................................................................................. 22
   TABLE 3: HCV Treatment Recommendations for HCV in Liver Transplant Recipients 22
   Chronic Kidney Disease (CKD) ........................................................................... 23
   Pregnancy ............................................................................................................ 24

REFERENCES ........................................................................................................... 25

GLOSSARY OF ABBREVIATIONS ............................................................................ 26
APPENDIX 1. TREATMENT OPTIONS FOR HCV GENOTYPES 1, 4, 5, AND 6A,B,C .......................................................... 27
APPENDIX 2. TREATMENT OPTIONS FOR HCV GENOTYPES 2 AND 3 A,B,C .......................................................... 28
APPENDIX 3. HEPATITIS C TREATMENT MONITORING SCHEDULE ................................................................. 29
APPENDIX 4. MANAGEMENT OF HEMATOLOGIC CHANGES ................................................................................. 30
APPENDIX 5. RESOURCES—PREVENTION AND TREATMENT OF VIRAL HEPATITIS ............................................ 31
APPENDIX 6. HEPATITIS C TREATMENT ALGORITHM/NONFORMULARY REQUEST WORKSHEET ...................... 32
1. PURPOSE AND OVERVIEW

The Federal Bureau of Prisons (BOP) Clinical Guidance on Evaluation and Management of Chronic Hepatitis C Virus (HCV) Infection provides the most current BOP recommendations for the treatment of chronic HCV infection in the federal inmate population. As stated by the current American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) HCV Guidance, the goal of treatment of HCV-infected persons is to:

… reduce all-cause mortality and liver-related health adverse consequences, including end-stage liver disease and hepatocellular carcinoma, by the achievement of virologic cure as evidenced by a sustained virologic response.

In light of the rapidly changing HCV treatment landscape, review of the most recent recommendations from AASLD/IDSA (see link below) is recommended. BOP Central Office Clinical staff will continue to monitor this guidance and provide updates as necessary.

→ Be sure to consult the BOP Health Management Resources website to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp.

→ The AASLD/IDSA guidance is available at https://www.hcvguidelines.org. See the References section in this document for a complete citation.

In general, the BOP promotes a modified test-and-treat strategy for HCV infection. The BOP-recommended approach to evaluation and management of HCV includes five basic steps.

**STEP 1:** Test for HCV infection with anti-HCV (HCV Ab) test.

→ See Section 2, Screening for HCV Infection.

• All inmates
• Diagnostic evaluation of other conditions
• Upon inmate request

**STEP 2:** Perform a baseline evaluation of inmates who are anti-HCV positive.

→ See Section 3, Initial Evaluation of Anti-HCV Positive Inmates.

• Problem-focused history and physical exam
• Lab tests – CBC, PT/INR, liver panel, serum creatinine and eGFR, hepatitis B serology (HBsAg, anti-HBs, anti-HBc), HIV serology, quantitative HCV RNA viral load with reflex testing for HCV genotype

**STEP 3:** Assess for hepatic cirrhosis/compensation and BOP priority criteria for treatment, if HCV RNA is detectable.

• Assess for hepatic cirrhosis/compensation: Calculate APRI score if no obvious cirrhosis; Calculate Child-Turcotte-Pugh (CTP) score if cirrhosis is known or suspected (→ Section 4).
• Assess for BOP priority criteria for treatment of HCV (→ Section 5).

**STEP 4:** Perform a pretreatment assessment, if priority criteria for treatment are met.

• Determine the most appropriate direct-acting antiviral (DAA) regimen(s)
  ➤ DAA regimen selection is based on HCV genotype, cirrhosis, compensated or uncompensated liver disease, prior treatment history, presence of resistance associated substitutions, and drug interactions (→ Appendix 1 and Appendix 2).
  ➤ Refer to AASLD HCV guidance, DHHS antiretroviral guidelines, and manufacturers’ prescribing information for specific drug interactions (→ References).
• Obtain pretreatment labs within 90 days of starting treatment (→ Appendix 3).
• Submit Nonformulary Request (NFR) for Hepatitis C Treatment Algorithm; if approved, submit NFR(s) for specific DAA medication(s) (→ Appendix 6).
• Provide preventive health care for patients with cirrhosis.

**STEP 5:** Monitor patient during and after treatment.

• Start treatment with approved DAA regimen.
• Follow monitoring schedule described in Appendix 3.
2. SCREENING FOR HCV INFECTION

INMATE HISTORY AND PATIENT EDUCATION

A health history should be obtained from all newly incarcerated BOP inmates. In addition, these inmates should be provided with educational information regarding prevention and transmission, risk factors, testing, and medical management of HCV infection, in accordance with BOP policy. Health education efforts should make use of the BOP peer-oriented video on infectious diseases, Staying Alive, located in Section 5: A–Z Topics on the HSD Infection Control website.

SCREENING CRITERIA

Testing for HCV infection is recommended for (a) all inmates, (b) all inmates with certain clinical conditions, and (c) all inmates who request testing.

a. RISK FACTORS FOR SENTENCED INMATES

An opt out strategy of voluntary testing for HCV infection is recommended for all inmates, regardless of sentencing status, including new intakes and those already in population who have not been previously tested. An “opt out” approach involves an informed refusal of testing, rather than informed consent (or “opt in”) for testing. After informing a patient of the indications and plan for testing, the particular test is ordered and performed—unless the patient declines it. Testing is considered voluntary in that it is good clinical practice, but is not required by policy or law.

The AASLD, CDC, and USPSTF recommend risk factor-based and birth cohort screening for HCV infection. The incarcerated population is reported to have higher prevalence rates of HCV than the general population and is identified by the AASLD and USPSTF as a risk factor for which screening is recommended.

Other well-described risk factors, which should be considered when recommending HCV testing to inmates, include:

- Ever injected illegal drugs or shared equipment (including intranasal use of illicit drugs)
- Received tattoos or body piercings while in jail or prison, or from any unregulated source
- HIV or chronic hepatitis B virus (HBV) infection
- Received a blood transfusion or an organ transplant before 1992, received clotting factor transfusion prior to 1987, or received blood from a donor who later tested positive for HCV infection
- History of percutaneous exposure to blood
- Ever received hemodialysis
- Born to a mother who had HCV infection at the time of delivery
- Born between 1945 and 1965
b. **Clinical Conditions for Any Inmate**

HCV testing is recommended for all inmates with the following clinical conditions:

- A reported history of HCV infection without prior medical records to confirm the diagnosis
- Cirrhosis
- Elevated ALT levels of unknown etiology
- Evidence of extrahepatic manifestations of HCV – mixed cryoglobulinemia, membranoproliferative glomerulonephritis, porphyria cutanea tarda, vasculitis
- Potential exposure to HCV, e.g., chronic hemodialysis (screen alanine aminotransferase [ALT] monthly and anti-HCV semiannually), injection drug use or high-risk sexual behavior, exposure to blood or potentially infectious material (see BOP Clinical Guidance on Medical Management of Exposures)

**Screening Method**

The preferred screening test for HCV infection is an immunoassay that measures the presence of antibodies to HCV antigens, referred to as HCV Ab or anti-HCV. The presence of these antibodies only indicates a history of exposure to the HCV virus, but does not distinguish between active and resolved infection.

Initial testing with an HCV RNA test is recommended for cases with a known prior positive HCV Ab if they are at risk for reinfection or suspected of reinfection, and if they previously cleared the HCV spontaneously or achieved a sustained virologic response (SVR) with treatment.

**Refusal of Testing**

Inmates who decline testing at the baseline visit, should be counseled about and offered HCV testing during periodic preventive health visits.

- A treatment refusal form is recommended for every testing and treatment refusal.

**3. Initial Evaluation of Anti-HCV Positive Inmates**

Initial evaluation of anti-HCV positive inmates includes (a) a baseline history and physical examination, and (b) baseline lab tests. The inmate should also be (c) assessed regarding the need for preventive health interventions such as vaccines and screenings for other conditions, as well as (d) counseled with information on HCV infection.

Determining whether the patient meets BOP priority criteria for treatment is an important part of the initial evaluation of anti-HCV positive inmates:

- If cirrhosis is present, see Section 4, Assess for Hepatic Cirrhosis and Decompensation, to determine whether the liver disease is compensated or decompensated.
- Section 5, BOP Priority Criteria for Treatment, lists the clinical scenarios that will be used in the BOP to prioritize inmates for treatment.
BASELINE EVALUATION

A baseline clinician evaluation should be conducted for all inmates who are anti-HCV positive. At minimum, this evaluation should include the following elements:

a. **PROBLEM-FOCUSED HISTORY AND PHYSICAL EXAMINATION:**
   - Evaluate for signs and symptoms of liver disease, quantify prior alcohol consumption, and determine risk behaviors for acquiring HCV infection (see the section on risk factors under Screening Criteria above). Attempt to estimate the earliest possible date of infection, including when risk factors for exposures started and stopped, e.g., the time period in which the inmate engaged in injection drug use.
   - Evaluate for other possible causes of liver disease, especially alcoholism, nonalcoholic steatohepatitis (NASH), iron overload, and autoimmune hepatitis.
   - Inquire about prior treatment for HCV infection, specific medications used, dosages and duration of treatment, and outcomes, if known.

b. **LABORATORY TESTS:**
   Recommended baseline laboratory tests are listed in Appendix 3 and include the following:
   - Complete blood count (CBC); prothrombin time (PT) with International Normalization Ratio (INR); liver panel (albumin, total and direct bilirubin, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and alkaline phosphatase); serum creatinine; and calculated glomerular filtration rate (GFR).
     - Unexplained abnormalities should prompt additional diagnostic evaluations, as clinically indicated, to determine the underlying cause, e.g., low hemoglobin/platelet count or GFR.
   - Hepatitis B serology (HBsAg, anti-HBs, and anti-HBc) and HIV serology.
     - Refer to the relevant BOP Clinical Guidance for management of a positive HBsAg or HIV test.
   - Quantitative HCV RNA viral load testing, sensitive to ≤ 25 IU/ml, with reflex testing for HCV genotype, to determine if the inmate has active HCV infection and identify the HCV genotype.
     - Undetectable levels of HCV RNA indicate resolved infection or a false positive HCV Ab test. Such cases do not require ongoing follow-up or monitoring of this condition in a chronic care clinic.
   - Unless otherwise clinically indicated, testing for other causes of liver disease—e.g., antinuclear antibody (ANA), ferritin, iron saturation, ceruloplasmin—are not routinely ordered in the evaluation of a positive HCV Ab test.
   - A urine drug screen is recommended only if ongoing substance use is suspected or if it is otherwise clinically indicated.
c. Preventive Health Measures:

All inmates who are anti-HCV positive should be evaluated to assess the need for the preventive health interventions. Patients with liver disease should receive standard immunizations that are applicable to an otherwise healthy population, including the following:

- **Hepatitis B vaccine:** Indicated for susceptible inmates with chronic HCV infection. For foreign-born inmates, consider prescreening for hepatitis B immunity prior to vaccination.
  - *Inmates with evidence of liver disease should be priority candidates for hepatitis B vaccination.*
- **Hepatitis A vaccine:** Indicated for susceptible inmates with chronic HCV. For foreign-born inmates, consider prescreening for hepatitis A immunity prior to vaccination.
- **Influenza vaccine:** Offer to all HCV-infected inmates annually.
  - *Inmates with cirrhosis are high priority for influenza vaccine.*
- **Pneumococcal vaccine:** Recommended by the CDC’s Advisory Committee on Immunization Practices (ACIP) for use in adults with chronic liver disease, including cirrhosis, regardless of age. Evidence for its use in chronic HCV infection without cirrhosis is limited. (Refer to BOP Clinical Guidance on Immunization for specific recommendations.)

d. Patient Education:

Inmates diagnosed with chronic HCV infection should be counseled by a health care provider regarding the natural history of the infection, potential treatment options, and specific measures to prevent transmitting HCV infection to others (both during incarceration and upon release).

4. Assess for Hepatic Cirrhosis and Decompensation

Cirrhosis is a condition of chronic liver disease marked by inflammation, degeneration of hepatocytes, and replacement with fibrotic scar tissue. The natural history of HCV is such that 50–80% of HCV infections become chronic. Progression of chronic HCV infection to fibrosis and cirrhosis may take years in some patients and decades in others—or, in some cases, may not occur at all. Most complications from HCV infection occur in people with cirrhosis.

- Patients with advanced hepatic fibrosis (primarily stage 3) have a 10% per year rate of progressing to cirrhosis (stage 4).
- Those with cirrhosis have a 4% per year rate of developing decompensated cirrhosis, and a 3% per year rate of developing hepatocellular carcinoma.

  - *The Child-Turcotte-Pugh (CTP) score is a useful tool in determining the severity of cirrhosis and in distinguishing between compensated and decompensated liver disease. See the discussion under Assessing Hepatic Compensation.*
ASSESSING FOR HEPATIC FIBROSIS AND CIRRHOSIS

Assessing for advanced fibrosis and cirrhosis is recommended for all inmates with HCV infection in order to select the most appropriate treatment regimen, prioritize inmates for treatment of HCV, and determine the need for additional health care interventions. Cirrhosis may be diagnosed in several ways:

• **Symptoms and signs that support the diagnosis of cirrhosis may include:** Low albumin or platelets, elevated bilirubin or INR, ascites, esophageal varices, and hepatic encephalopathy. However, isolated lab abnormalities may require additional diagnostic evaluation to determine the etiology.

• **The AST-Platelet Ration Index (APRI) is the BOP-preferred method for non-invasive assessment of hepatic fibrosis and cirrhosis:**
  - The APRI score, a calculation based on results from two blood tests—the AST (aspartate aminotransferase) and the platelet count—is a less invasive and less expensive means of assessing fibrosis than a liver biopsy. **If a person is known to have cirrhosis, the APRI is irrelevant and unnecessary.**
  - The formula for calculating the APRI score is: \[\frac{[(\text{AST} / \text{AST ULN}) \times 100]}{\text{platelet count (10}^9/\text{L})}\].
  - A calculator is available at: [http://www.hepatitisc.uw.edu/page/clinical-calculators/apri](http://www.hepatitisc.uw.edu/page/clinical-calculators/apri)
  - **An APRI score ≥ 2.0 may be used to predict the presence of cirrhosis.** At this cutoff, the APRI score has a sensitivity of 48%, but a specificity of 94%, for predicting cirrhosis. Inmates with an APRI score ≥ 2.0 should have an abdominal ultrasound performed to identify other findings consistent with cirrhosis (see abdominal imaging studies bullet below in this list). Lower APRI scores have different sensitivities and specificities for cirrhosis. For example, an APRI score ≥ 1 has a sensitivity of 77% and a specificity of 75% for predicting cirrhosis.
  - The APRI may also be used to predict the presence of significant fibrosis (stages 2 to 4, out of 4). Using a cutoff of ≥ 0.7, the sensitivity is 77% and specificity is 72% for significant fibrosis.
  - The APRI score may be invalidated in cases of splenectomy. An alternative non-invasive test, e.g., Fibrosure, may be appropriate.

• **Liver biopsy is no longer required** unless otherwise clinically indicated or if there is uncertainty about the stage of fibrosis, based on results from non-invasive testing or other clinical indicators. However, the presence of cirrhosis on a prior liver biopsy may be used to meet the BOP criteria for HCV treatment.

• **Although a combination of direct biomarkers and transient elastography is emerging as an accurate non-invasive assessment of fibrosis,** the data is insufficient at this time to establish it as the new standard over validated indirect biomarkers such as the APRI score.

• **Abdominal imaging studies** such as ultrasound or CT scan may identify findings consistent with or suggestive of the following: **cirrhosis** (nodular contour of the liver), **portal hypertension** (ascites, splenomegaly, varices), or **hepatocellular carcinoma** (HCC).

Abdominal ultrasound is routinely performed in cases of known or suspected cirrhosis, and as clinically indicated on a case-by-case basis.
ASSESSING HEPATIC COMPENSATION

Assessing hepatic compensation is important for determining the most appropriate HCV treatment regimen to be used. The recommended HCV treatment regimen may differ depending on whether the cirrhosis is compensated or decompensated.

The CTP score is a useful tool to help determine the severity of cirrhosis and is used by the AASLD to distinguish between compensated and decompensated liver disease in patients with known or suspected cirrhosis.

➤ CTP calculators are readily available on the Internet and are not reproduced in this document. See: http://www.hepatitisc.uw.edu/page/clinical-calculators/ctp

The CTP score includes five parameters (albumin, bilirubin, INR, ascites, and hepatic encephalopathy), each of which is given a score of 1, 2, or 3. The sum of the five scores is the CTP score, which is classified as shown in Table 1 below:

<table>
<thead>
<tr>
<th>CTP Score</th>
<th>CTP Class</th>
<th>Hepatic Compensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>5–6</td>
<td>Class A</td>
<td>Compensated cirrhosis</td>
</tr>
<tr>
<td>7–9</td>
<td>Class B</td>
<td>Decompensated cirrhosis</td>
</tr>
<tr>
<td>≥ 10</td>
<td>Class C</td>
<td></td>
</tr>
</tbody>
</table>

Notes:
➤ Warfarin anticoagulation will invalidate CTP calculations if the INR is 1.7 or higher.
➤ It is recommended that cases of decompensated cirrhosis be managed in consultation with a clinician experienced in the treatment of this condition.
➤ Inmates with CTP Class C decompensated cirrhosis may have a reduced life expectancy and should be considered for Reduction In Sentence/Compassionate Release in accordance with current policy (Compassionate Release/Reduction in Sentence) and procedures.

ADDITIONAL INTERVENTIONS FOR INMATES WITH CIRRHOSIS

The following recommendations apply to all inmates with cirrhosis, whether they have ongoing or resolved HCV infection.

• Pneumococcal vaccine: Offer to all HCV-infected inmates with cirrhosis.
  ➤ See the BOP Clinical Guidance on Immunization.

• Hepatocellular carcinoma (HCC) screening: Liver ultrasound is recommended every six months for patients with both cirrhosis and chronic HCV infection.

• Esophageal varices screening: Screening for esophageal and gastric varices with esophagogastroduodenoscopy (EGD) is recommended for patients diagnosed with cirrhosis.

Other healthcare interventions recommended for patients with cirrhosis may include:

• Nonselective beta blockers for prevention of variceal bleeding in patients with esophageal varices.
• Antibiotic prophylaxis if risk factors are present for spontaneous bacterial peritonitis.
• Optimized diuretic therapy for ascites.
• Lactulose and rifaximin therapy for encephalopathy.

In general, NSAIDs should be avoided in advanced liver disease/cirrhosis, and metformin should be avoided in decompensated cirrhosis. The detailed management of cirrhosis is beyond
the scope of this document. Other resources should be consulted for more specific recommendations related to this condition.

5. BOP PRIORITY CRITERIA FOR HCV TREATMENT

SVR (virologic cure) rates of 90% or higher can be achieved with current DAA regimens. Eradication of HCV is associated with a number of improved outcomes, including a reduction in the following: liver inflammation and fibrosis, severity of advanced liver disease and its complications, risk of liver cancer and liver-related mortality, need for liver transplantation, and transmission of HCV infection.

All sentenced inmates with chronic HCV infection are eligible for consideration of treatment. Certain cases are at higher risk for complications or disease progression and may require more urgent consideration for treatment. The BOP has established PRIORITY CRITERIA to ensure that inmates with the greatest need are identified and treated first. Additional criteria for treatment have also been established (see Other Criteria For Treatment).

PRIORITY LEVEL 1: HIGH PRIORITY FOR TREATMENT *

- ADVANCED HEPATIC FIBROSIS
  - APRI ≥ 2.0, or
  - Metavir or Batts/Ludwig stage 3 or 4 on liver biopsy, or
  - Known or suspected cirrhosis

- LIVER TRANSPLANT RECIPIENTS

- HEPATOCELLULAR CARCINOMA (HCC)

- COMORBID MEDICAL CONDITIONS ASSOCIATED WITH HCV, INCLUDING:
  - Cryoglobulinemia with renal disease or vasculitis
  - Certain types of lymphomas or hematologic malignancies
  - Porphyria cutanea tarda

- IMMUNOSUPPRESSANT MEDICATION FOR A COMORBID MEDICAL CONDITION
  - Some immunsuppressant medications (e.g., certain chemotherapy agents and tumor necrosis factor inhibitors) may be needed to treat a comorbid medical condition, but are not recommended for use when infection is present. Although data are insufficient and current guidelines are inconsistent regarding treatment of HCV infection in this setting, such cases will be considered for prioritized treatment of HCV on an individual basis.

- CONTINUITY OF CARE FOR THOSE ALREADY STARTED ON TREATMENT, including inmates who are newly incarcerated in the BOP.

PRIORITY LEVEL 2: INTERMEDIATE PRIORITY FOR TREATMENT *

- EVIDENCE FOR PROGRESSIVE FIBROSIS
  - APRI score ≥ 0.7
  - Stage 2 fibrosis on liver biopsy

(PRIORITY LEVEL 2 criteria continues on next page)
• **COMORBID MEDICAL CONDITIONS** associated with more rapid progression of fibrosis
  ▶ Coinfection with HBV or HIV
  ▶ Comorbid liver diseases (e.g., autoimmune hepatitis, hemochromatosis, fatty infiltration of the liver, steatohepatitis)
  ▶ Diabetes mellitus

• **CHRONIC KIDNEY DISEASE (CKD)** with GFR ≤ 59 mL/min per 1.73 m²

• **BIRTH COHORT 1945–1965**

**PRIORITY LEVEL 3: LOW PRIORITY FOR TREATMENT** *

• Stage 0 to stage 1 fibrosis on liver biopsy
• APRI < 0.7
• All other cases of HCV infection meeting the eligibility criteria for treatment, as noted right below under *Other Criteria for Treatment*.

**OTHER CRITERIA FOR TREATMENT**

*In addition to meeting the above criteria for PRIORITY LEVELS 1–3, inmates being considered for treatment of HCV infection should:*

• Have no contraindications to, or significant drug interactions with, any component of the treatment regimen.

• Not be pregnant, especially for any regimen that would require ribavirin or interferon.

• Have sufficient time remaining on their sentence in the BOP to complete a course of treatment.
  ➔ *Inmates with high priority criteria (PRIORITY LEVEL 1), but insufficient time remaining in BOP custody, may be considered for treatment if they will have access to medications and health care providers for continuity of care at the time of release.*
  ➔ *Long-term, pre-sentence detainees in BOP custody with high priority criteria may be considered for treatment if continuity of care can be reasonably assured and there is reliably sufficient time remaining in custody to complete treatment.*

• Have a life expectancy > 18 months.

• Demonstrate a willingness and an ability to adhere to a rigorous treatment regimen and to abstain from high-risk activities while incarcerated.
  ➔ *Inmates with evidence for ongoing high-risk behaviors, e.g., injection drug use, are considered for HCV treatment on an individual basis. Referral for evaluation and treatment of substance abuse is recommended.*
6. **RECOMMENDED TREATMENT REGIMENS**

<table>
<thead>
<tr>
<th>Recommendations for preferred HCV treatment regimens continue to evolve, but still depend on several factors:</th>
</tr>
</thead>
<tbody>
<tr>
<td>► HCV GENOTYPE</td>
</tr>
<tr>
<td>► PRIOR HCV TREATMENT HISTORY</td>
</tr>
<tr>
<td>► COMPENSATED VS. DECOMPENSATED LIVER DISEASE</td>
</tr>
<tr>
<td>► RESISTANCE-ASSOCIATED SUBSTITUTIONS (CERTAIN CLINICAL SCENARIOS)</td>
</tr>
<tr>
<td>► DRUG-DRUG INTERACTIONS</td>
</tr>
</tbody>
</table>

**SPECIAL CONSIDERATIONS:** Certain conditions require special consideration when selecting an HCV treatment regimen, including decompensated cirrhosis, chronic kidney disease, solid organ transplant recipients, and pregnancy. These SPECIAL CONDITIONS are addressed in Section 8.

**COST:** The cost of direct acting antiviral (DAA) regimens can vary widely. When more than one regimen is appropriate for an individual case, the most cost-effective regimen is recommended, taking into consideration all the factors listed in the BOX above.

**DIRECT ACTING ANTIVIRAL MEDICATIONS (DAAs)**

As the name implies, these antiviral medications for HCV infection act directly on some part of the virus, usually the replication mechanism.

Currently, there are three classes of HCV DAAs: polymerase inhibitors (-buvir), protease inhibitors (-previr), and NS5A replication complex inhibitors (-asvir).

**DAAs cannot be used as monotherapy; they must be used in combination with at least one other DAA or with ribavirin, and in some cases with peginterferon, depending on the clinical scenario.**

**The most commonly recommended regimens are briefly described below.** More detailed information about the regimens and the individual medications—including indications, contraindications, dosing and duration, and drug interactions—may be found in the the AASLD guidance, manufacturer’s prescribing information, Facts and Comparisons (available in BEMR), and other validated resources.

**DACLATASVIR + SOFOSBUVIR**

- **USE:** Once-daily daclatasvir coadministered with 400 mg of sofosbuvir once daily, with or without food, is FDA-approved for the treatment of **HCV genotype 1 and 3**.
  - AASLD currently recommends this combination as an option for treatment of **HCV genotypes 1, 2, 3, and 4** in various clinical scenarios with **decompensated cirrhosis**.
  - If there are no contraindications, ribavirin is added to the regimen in decompensated cirrhosis and in some HCV treatment-experienced cases.

- **DOSING:** The usual dose of daclatasvir is 60 mg once daily, with or without food.
  - Dosage adjustment is required with strong CYP3A inhibitors (30 mg once daily) and with moderate CYP3A inducers (90 mg once daily).
  - **Daclatasvir is contraindicated with strong CYP3A inducers (e.g., carbamazepine, phenytoin, and rimamycin antimycobacterials) and is not recommended with amiodarone.**
► When coadministered with antiretrovirals for HIV infection—the dose of daclatasvir is decreased to 30 mg with indinavir, nelfinavir, saquinavir, ritonavir-boosted atazanavir, or any cobicistat-containing regimen except darunavir; the dose of daclatasvir is increased to 90 mg with efavirenz, etravirine, or nevirapine.

• **Duration:** The usual duration of treatment is 12 weeks in patients with no cirrhosis,

► Response rates are diminished in cirrhosis; the optimal duration for treatment of HCV with cirrhosis is not well-established, but AASLD recommends longer treatment durations of 16 to 24 weeks, depending on the clinical scenario.

### Elbasvir/Grazoprevir (Zepatier®)

• **Formulation/Use:** A coformulation of 50 mg of elbasvir (an HCV NS5A inhibitor) and 100 mg of grazoprevir (an HCV NS3 protease inhibitor) is FDA-approved for treatment of HCV genotypes 1 and 4.

► In HCV genotype 1a, NS5A resistance testing is recommended prior to treatment, if GFR is ≥30.

• **Dosing and Duration:** The usual dose and duration is one tablet orally once daily, with or without food, for 12 weeks.

► 16 weeks is recommended for **HCV genotype 1a** with baseline NS5A polymorphisms or for **HCV genotype 4** treatment-experienced with peginterferon + ribavirin.

► Sofosbuvir is added to elbasvir/grazoprevir when treating **HCV genotype 3** with compensated cirrhosis and previously treated with pegylated interferon + ribavirin.

► Weight-based ribavirin is added to elbasvir/grazoprevir for the following: **HCV genotype 1a** with baseline NS5A polymorphisms; **HCV genotype 1a or 1b** treatment-experienced with PEG-peginterferon + ribavirin + HCV protease inhibitor; or **HCV genotype 4** treatment-experienced with peginterferon + ribavirin.

► No dosage adjustment is required for decreased renal function or hemodialysis, although the ribavirin dose must be adjusted for GFR < 50.

• **Contraindications and Use Not Recommended:**

► Elbasvir/grazoprevir is contraindicated in decompensated cirrhosis (CTP score ≥ 7), or with certain medications.

► Contraindicated medications include phenytoin, carbamazepine, rifampin, efavirenz, HIV protease inhibitors (atazanavir, darunavir, lopinavir, saquinavir, and tipranavir), and cyclosporine.

► Elbasvir/grazoprevir is not recommended with moderate CYP3A inducers or with strong CYP3A inhibitors.

### Glecaprevir/Pibrentasvir (Mavyret®)

• **Formulation/Use:** A coformulation of 100 mg of glecaprevir and 40 mg of pibrentasvir is FDA-approved for treatment of **HCV genotypes 1, 2, 3, 4, 5, or 6**, without cirrhosis or with compensated cirrhosis (Child-Pugh A). Glecaprevir/pibrentasvir is also indicated for the treatment of adult patients with **HCV genotype 1** infection, previously treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
• **Dosing and Duration:** The usual dose is three tablets (total daily dose: glecaprevir 300mg and pibrentasvir 120mg) taken orally, once daily, with food, for treatment-naïve patients. No dosage adjustment is required in patients with mild, moderate, or severe renal impairment, including those on dialysis. The usual duration of treatment is 12 weeks, except as noted below:
  - Treatment duration of 8 weeks is recommended for all genotypes with no cirrhosis if they are treatment-naïve or treatment-experienced with PEG-IFN + RBV.
  - Treatment duration of 16 weeks is an AASLD alternative regimen for:
    1) **HCV genotype 1**, without cirrhosis or with compensated cirrhosis (Child-Pugh A), in patients who are treatment-experienced with an NS5A inhibitor without prior treatment with an NS3/4A inhibitor; and
    2) **HCV genotype 3**, without cirrhosis or compensated cirrhosis (Child-Pugh A), in patients who are treatment-experienced with PEG-IFN and RBV, with or without SOF.

• **Uses Not Recommended:**
  - Glecaprevir/pibrentasvir is not recommended for use with certain medications (e.g., carbamazepine, efavirenz, and St. John’s wort).
  - Glecaprevir/pibrentasvir is not recommended for use with moderate hepatic impairment (Child-Pugh B).

• **Contraindication:** It is contraindicated with severe hepatic impairment (Child-Pugh C) or with coadministration with atazanavir and rifampin.

• **Warning:** Risk of Hepatitis B virus reactivation in patients coinfected with HCV and HBV.

**Ledipasvir/Sofosbuvir (Harvoni®)**

• **Formulation/Use:** A coformulation of 90 mg of ledipasvir and 400 mg of sofosbuvir is FDA-approved for treatment of **HCV genotypes 1, 4, 5, and 6**; alone or in combination with ribavirin, without or with cirrhosis, compensated or decompensated.

• **Dosing and Duration:** The usual dose is one tablet orally once daily, with or without food, for 12 or 24 weeks, depending on the clinical scenario.
  - AASLD recommends only an 8-week course of treatment in a subgroup of HCV-infected persons who have **genotype 1a or 1b**, have an HCV viral load <6 million IU/ml, and are treatment-naïve—but who are not black, are not HIV-coinfected, and do not have cirrhosis.

• **Uses Not Recommended:**
  - Ledipasvir/sofosbuvir is not recommended for use with certain anticonvulsants (e.g., carbamazepine, phenytoin, phenobarbital, or oxcarbazepine), certain rifamycin antimycobacterials (e.g., rifabutin, rifampin, or rifapentine), or the antiarrhythmic, amiodarone.
  - The dose and safety of ledipasvir/sofosbuvir is unknown in severe renal impairment; it is not recommended by AASLD in CKD with GFR < 30 mL/min/1.73m².
PARITAPREVIR/RITONAVIR/OMBITASVIR/DASABUVIR (VIEKIRA XR™)

- **Formulation:** This treatment includes three tablets, each coformulated with 50 mg of paritaprevir, 33.33 mg of ritonavir, 8.33 mg of ombitasvir, and 200 mg tablets of dasabuvir.

- **Use:** This is an FDA-approved treatment of **HCV genotype 1**, alone (for **genotype 1b**) or in combination with ribavirin (for **genotype 1a**).
  - AASLD also recommends this as a treatment option for **HCV genotype 1b** with CKD and GFR < 30 for whom urgent HCV treatment is needed.

- **Dosing and Duration:** The usual dose is three tablets once daily with a meal. Duration of treatment is either 12 weeks for **genotype 1a** without cirrhosis, or **genotype 1b** with or without compensated cirrhosis; or 24 weeks for **genotype 1a** with compensated cirrhosis.

- **Contraindication:** This treatment is contraindicated for use with decompensated cirrhosis.

SOFOSBUVIR/VELPATASVIR (EPCLUSA®)

- **Formulation/Use:** A coformulation of 400 mg of sofosbuvir and 100 mg of velpatasvir is FDA-approved for treatment of **HCV genotypes 1, 2, 3, 4, 5, and 6**, with no cirrhosis or with compensated cirrhosis, or for decompensated cirrhosis in combination with ribavirin.

- **Dosing and Duration:** The usual dose is one tablet orally once daily, with or without food, for 12 weeks.

- **Uses Not Recommended:**
  - Sofosbuvir/velpatasvir is not recommended for use with certain anticonvulsants (e.g., carbamazepine, phenytoin, phenobarbital, or oxcarbazepine), certain rifamycin antimycobacterials (e.g., rifabutin, rifampin, or rifapentine), the antiarrhythmic amiodarone, certain antiretrovirals (efavirenz, or tipranavir/ritonavir), or proton pump inhibitors.
  - The dose and safety of sofosbuvir/velpatasvir is unknown in severe renal impairment; it is not recommended in CKD with GFR < 30 mL/min/1.73m².

- **Contraindication:** If there are contraindicatons to ribavirin, it should not be used in combination with sofosbuvir/velpatasvir.

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR (VOSEVI®)

- **Formulation/Use:** A coformulation of 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir is FDA-approved for treatment of adult patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) with **HCV genotypes 1, 2, 3, 4, 5, or 6**, infections previously treated with a regimen containing an NS5A inhibitor, or **HCV genotypes 1a or 3** infection previously treated with sofosbuvir without an NS5A inhibitor.

- **Dosing and Duration:** The usual dose is one tablet (total daily dose: 400 mg of sofosbuvir, 100mg of velpatasvir, and 100mg of voxilaprevir) taken orally, once daily, with food, for 12 weeks for **HCV genotypes 1, 2, 3, 4, 5, or 6** previously treated with an NS5A inhibitor or **HCV genotypes 1a or 3** treated with sofosbuvir without an NS5A inhibitor. A dosage recommendation cannot be made for patients with severe renal impairment or end stage reanl disease.
• **Uses Not Recommended:**
  - Not recommended for use with P-gp inducers and/or moderate to potent CYP inducers (e.g., carbamazepine, St. John’s wort).
  - Sofosbuvir/velpatasvir/voxilaprevir is not recommended for use with moderate hepatic impairment (Child-Pugh B).

• **Contraindication:** It is contraindicated with severe hepatic impairment (Child-Pugh C) or with coadministration with Rifampin.

• **Warning:**
  - Sofosbuvir/velpatasvir/voxilaprevir is not recommended for use with moderate hepatic impairment (Child-Pugh B).
  - Serious bradycardia may occur with amiodarone coadministration, particularly in patients receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease. In patients without alternative viable treatment options, cardiac monitoring is recommended.

**Sofosbuvir + Simeprevir**

• **Dosing/Duration/Use:** Taken together once daily, 400 mg of sofosbuvir and 150 mg of simeprevir, for 12 weeks in patients with no cirrhosis.
  - When used as an alternative regimen to treat patients with compensated cirrhosis, the duration is extended to 24 weeks, with or without ribavirin.
  - This combination is FDA-approved for treatment of **HCV genotype 1**.
    - **When used for the treatment of HCV genotype 1a with cirrhosis,** a test for HCV NS3 virologic resistance looking for the Q80K polymorphism must be obtained prior to treatment.

**Preferred Treatment Regimens**

The preferred treatment regimens currently recommended by AASLD/IDSA are included in this BOP guidance in the following appendices:

- [Appendix 1, Treatment Recommendations for HCV with Compensated Cirrhosis](#)
- [Appendix 2, Treatment Recommendations for HCV with No Cirrhosis](#)

Please refer to the AASLD/IDSA website ([www.hcvguidelines.org](http://www.hcvguidelines.org)) for any updates since September 21, 2017.

**Alternative Treatment Regimens:** The AASLD/IDSA guidance includes recommendations for some regimens that are not specifically FDA-approved and also describe alternative treatment regimens for situations in which a preferred regimen is not an option. These alternative regimens are not included in this BOP guidance, but can be considered on a case-by-case basis.
**POTENTIAL DRUG INTERACTIONS**

In addition to the genotype, prior HCV treatment history, and status of hepatic compensation, as noted above, it is essential to review each treatment candidate for potential drug interactions prior to selecting the most appropriate regimen for HCV treatment. Adjustments of the inmate’s current medications may be needed prior to starting treatment for HCV. Refer to the appendices at the end of this document for specific drug interactions. Other useful resources for potential drug interactions include the AASLD/IDSA guidance, the individual manufacturers’ prescribing information, and the DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.

**REGIMENS NOT RECOMMENDED**

*Regimens that are not recommended for use include the following:*

- Monotherapy with peginterferon, ribavirin, or any of the DAAs.
- Dual therapy with peginterferon and ribavirin, except when urgent HCV treatment is needed for **genotypes 2, 3, 5, or 6** with GFR < 30.
  - See discussion of **chronic kidney disease** in Section 8.
- Triple therapy with peginterferon, ribavirin, and the HCV protease inhibitors boceprevir, simeprevir, or telaprevir.
- HCV protease inhibitors for **genotypes 2, 3, 5, or 6** (paritaprevir, simeprevir).

**7. MONITORING**

- See **Appendix 3, Hepatitis C Treatment Monitoring Schedule**, for a summary chart of the monitoring recommendations.

**PRETREATMENT ASSESSMENT**

*Prior to starting treatment for HCV infection, patient education is recommended*—including, but not limited to: how to take the medication, the importance of adherence, monitoring and follow up, and potential medication side effects. When ribavirin is used, specific counseling about the risks and recommendations related to pregnancy should be provided.

*Pretreatment assessment should be accomplished within three months of the projected start of treatment, and should include the following:*

- **Laboratory tests** including CBC, PT/INR, liver panel, serum creatinine, calculated GFR.
  - Obtain quantitative HCV RNA viral load and HCV genotype if the most recent results are more than one year old or if not previously performed.
  - A urine drug screen is not required as part of the pretreatment evaluation, and is recommended only if ongoing substance use is suspected or if it is otherwise clinically indicated.
- **Calculation of the APRI score** using results from the pretreatment labs. (An APRI score is not needed if there is confirmed cirrhosis.)

(PRETREATMENT ASSESSMENT list continues on next page)
• **Calculation of current CTP score** for inmates with known or suspected cirrhosis.
• **Assessment for significant drug-drug interactions.**
• **Assessment for current/prior medication adherence.**
• **Review of incident report history** for high-risk behaviors (alcohol/drug possession/use; tattooing).

**For ribavirin-containing regimens:** In addition to the above, obtain a pregnancy test in all women with childbearing potential. A pretreatment ECG is recommended for inmates with preexisting coronary heart disease.

**For interferon-containing regimens:** In addition to the above, pretreatment evaluation should include a WBC with differential, TSH/free T4. Such regimens should also include a mental health evaluation.

*Testing for NS5A resistance-associated substitutions (RASs) is recommended prior to treatment with the following regimens or situations:*

• Elbasvir/grazoprevir for **HCV genotype 1a** and GFR ≥30.
• Sofosbuvir/velpatasvir for treatment-naïve **HCV genotype 3** with cirrhosis.
• Sofosbuvir/velpatasvir for **HCV genotype 3** treatment-experienced with PEG-IFN + RBV and no cirrhosis.
• Daclatasvir + sofosbuvir as an alternative regimen for treatment-naïve **HCV genotype 3** with cirrhosis.
• Daclatasvir + sofosbuvir as an alternative regimen for **HCV genotype 3** treatment-experienced with PEG-IFN + RBV, and no cirrhosis.
• NS5A resistance testing may be considered when ledipasvir/sofosbuvir is an option for treatment-experienced **HCV genotype 1a** with no cirrhosis or compensated cirrhosis.
  ➔ **NS3/4A resistance testing is no longer routinely recommended.**

**ON-TREATMENT MONITORING**

*On-treatment monitoring should include the following:*

• **An outpatient clinic visit at 2 weeks and at 4 weeks** after starting therapy, and monthly thereafter; more frequently as clinically indicated.
  ➔ The primary focus at the 2-week visit is assessment of medication adherence, side effects and symptoms of hepatic decompensation, adverse drug reactions, and drug-drug interactions.

• **Labs drawn at 4 weeks** after the start of therapy should include CBC, serum creatinine, calculated GFR, liver panel including ALT, and quantitative HCV viral load sensitive to ≤ 25 IU/ml; others as clinically indicated.
  ➔ **For regimens containing interferon and/or ribavirin:** A CBC should also be drawn 2 weeks after starting therapy, then at 4 weeks, then monthly; more frequently as clinically indicated. Interferon and/or ribavirin dosage adjustments may be required.
    ➔ See Appendix 4, *Management of Hematologic Changes.*

*(ON-TREATMENT MONITORING list continues on next page)*
More frequent monitoring of ALT is necessary in certain situations:

- **Regimens containing elbasvir/grazoprevir:** For 12-week regimens, a liver panel including ALT should be drawn at 4 weeks and again at 8 weeks, and as clinically indicated. For 16-week regimens, a liver panel including ALT should be drawn at 4 weeks and again at 12 weeks.

- **Patients with compensated cirrhosis** who are treated with paritaprevir/ritonavir/ombitasvir (with or without dasabuvir) require monitoring by a liver panel—including ALT and signs of decompensated liver disease—at 2 weeks, 4 weeks, and as clinically indicated.

- **Increases in the ALT should prompt more frequent monitoring or early discontinuation.** Asymptomatic ALT increases of less than tenfold should be monitored approximately every 2 weeks. Early discontinuation of HCV treatment is recommended if ALT increases by tenfold—or if less than tenfold, but accompanied by symptoms such as weakness, anorexia, nausea, vomiting, or change in stool color, or signs including elevations in conjugated bilirubin, alkaline phosphatase, and INR, related to hepatic dysfunction.

- **If the quantitative HCV viral load is detectable after 4 weeks of treatment,** it should be repeated 2 weeks later. Early discontinuation of HCV treatment is recommended only if there is > 1 log increase from the nadir in HCV viral load after 6 weeks or more of treatment.

  - *HCV viral load testing is no longer required at the end of treatment, but should be obtained in all cases that failed to achieve undetectable levels during treatment.*

- **A test for thyroid stimulating hormone (TSH)** is recommended every 12 weeks only for patients receiving regimens containing interferon. For a 12-week regimen, a TSH should be drawn at the end of treatment, in addition to the pretreatment baseline.

- **Pregnancy testing is required prior to treatment with ribavirin-containing regimens,** and then periodically during and after treatment—usually monthly during treatment and for 6 months after completion of treatment.

- **Monitoring of interferon and/or ribavirin-containing regimens** has not changed and is included in *Appendix 3, Hepatitis C Treatment Monitoring Schedule.*

- **For patients with evidence of chronic HBV infection (i.e., HBsAg positive) who do not meet criteria for antiviral HBV therapy,** quantitative HBV DNA levels are recommended prior to starting HCV DAA treatment, periodically during DAA treatment (usually every four weeks), and immediately after DAA treatment. Initiate antiviral HBV treatment if the HBV DNA level increases more than 10-fold from baseline or above 1,000 IU/ml if it was previously undetectable.
POST-TREATMENT MONITORING

• A quantitative HCV RNA viral load assessment is recommended at 12 weeks after completion of treatment; if HCV is undetectable, it defines an SVR.

• If the HCV viral load is again undetectable at 6 to 12 months after the end of treatment, the inmate may be removed from the chronic care clinic for this condition, so long as he or she has no cirrhosis, complications, or related comorbidities, and the HCV infection has been changed to “resolved” in the problem list.

➔ Recurrent viremia following an SVR may be due to relapse or reinfection. To help distinguish between the two in such cases, an HCV genotype, along with subtyping for genotype 1, should be obtained. If the post-SVR genotype is the same as the pre-treatment genotype, it is not possible to distinguish relapse from reinfection.

ONGOING MONITORING

*Periodic monitoring is recommended for all those with active infection*, including acute HCV infection, HCV treatment failures, relapse of HCV infection or reinfection, and those with chronic HCV infection who are not yet treated.

• **For cases without advanced fibrosis, cirrhosis, or complications**, annual evaluation is appropriate. This evaluation should include a focused review of systems and patient education relevant to HCV, vital signs and a focused physical examination, and lab monitoring (CBC, PT/INR, liver panel, serum creatinine, calculated GFR, and calculation of the APRI score).

• **For patients with cirrhosis or significant comorbidities**, evaluation is recommended at least every six months; more frequently as clinically indicated.

• **In cases of acute HCV infection**, monitoring for spontaneous clearance of the infection with ALT and quantitative HCV RNA levels every four to eight weeks, for six to twelve months, is recommended. If viremia persists after that time, continue to monitor and manage the case as a chronic infection. In most cases of acute HCV infection, treatment may be deferred to allow for spontaneous clearance of viremia. However, in some cases there may be a compelling reason to treat the acute infection in order to prevent severe complications, e.g., HCV infection superimposed on established cirrhosis or advanced fibrosis.
8. SPECIAL CONSIDERATIONS

HCV INFECTION WITH MORE THAN ONE GENOTYPE

Very little data are available to guide the selection of a DAA regimen when more than one HCV genotype are present at the same time. In such cases, selection of a regimen that is effective against both of the existing genotypes is appropriate, in consultation with a BOP Hepatitis Clinical Pharmacy Consultant or Central Office Physician.

HBV COINFECTION

In patients coinfected with HBV and HCV, HBV reactivation may occur during or after treatment with HCV DAAs. Testing for HBV infection—including HBsAg, anti-HBs, and anti-HBc, as well as HBV DNA levels in those with a reactive HBsAg—is recommended for all patients being considered for treatment of HCV infection.

- **If criteria for treatment of HBV are met**, it is recommended that HBV treatment be started prior to or at the same time as HCV treatment, and monitored according to HBV treatment guidance.

- **If criteria for treatment of HBV infection are not met**, monitoring of HBV DNA is recommended every 4 weeks during HCV treatment and for 3 months after treatment is completed. Initiate antiviral HBV treatment if the HBV DNA level increases more than 10-fold from baseline or above 1,000 IU/ml if it was previously undetectable. Alternatively, HBV antiviral therapy may be prescribed during HCV treatment and for 3 months after treatment completion.

- **For isolated anti-HBc positive cases with negative HBsAg and anti-HBs**, monitor ALT at baseline, at the completion of HCV treatment, and again during post-treatment follow-up.

HIV COINFECTION

Currently recommended HCV regimens are equally effective for HCV mono-infection and coinfection with HIV. However, an alternative HCV regimen or an alternative antiretroviral medication regimen may be necessary due to potential drug interactions between the HCV DAAs and certain antiretrovirals.

The following are links to tables showing drug interactions between the HIV antiretrovirals and the HCV Direct Acting Antivirals (DAAs):

- [https://aidsinfo.nih.gov/guidelines/htmltables/1/5536](https://aidsinfo.nih.gov/guidelines/htmltables/1/5536) (Table 12)
- [https://www.hcvguidelines.org/unique-populations/hiv-hcv](https://www.hcvguidelines.org/unique-populations/hiv-hcv) (scroll to the bottom of the page)
DECOMPENSATED CIRRHOSIS

Treatment of HCV patients with decompensated cirrhosis should be managed in consultation with an experienced clinician/specialist, with treatment requests considered on a case-by-case basis. HCV treatment recommendations for patients with decompensated cirrhosis apply regardless of eligibility for a liver transplant or the presence of hepatocellular carcinoma. The regimens and other considerations are listed below. Inmates with decompensated cirrhosis and a CTP score ≥ 9 may meet reduction in sentence criteria

See TABLE 2 for a summary of treatment recommendations for decompensated cirrhosis.

HCV GENOTYPE 1, 4, 5, OR 6 WITH DECOMPENSATED CIRRHOSIS:

See the section that discusses the use of ribavirin with this group.

- The treatment options for HCV genotype 1, 4, 5, or 6 with decompensated cirrhosis, either treatment-naïve or treatment-experienced with peginterferon+ribavirin, are as follows:
  - Ledipasvir/sofosbuvir + low initial dose ribavirin for 12 weeks (or ledipasvir/sofosbuvir for 24 weeks in ribavirin-ineligible cases)
  - Sofosbuvir/velpatasvir + ribavirin for 12 weeks (or sofosbuvir/velpatasvir for 24 weeks in ribavirin-ineligible cases)
  - Genotypes 1 or 4 only: Daclatasvir + sofosbuvir + low initial dose ribavirin for 12 weeks (or daclatasvir + sofosbuvir for 24 weeks in ribavirin-ineligible cases)

- For cases with a history of treatment failure with a regimen containing sofosbuvir, one of the following two regimens is recommended:
  - Ledipasvir/sofosbuvir + low initial dose ribavirin for 24 weeks
  - Sofosbuvir/velpatasvir + ribavirin for 24 weeks

- For cases with a history of treatment failure with a regimen containing an NS5A inhibitor, the following regimen is recommended:
  - Sofosbuvir/velpatasvir + ribavirin for 24 weeks

HCV GENOTYPE 2 OR 3 WITH DECOMPENSATED CIRRHOSIS:

See the section that discusses the use of ribavirin with this group.

- The treatment options for HCV genotype 2 or 3 with decompensated cirrhosis, either treatment-naïve or treatment-experienced with peginterferon+ribavirin, are as follows:
  - Once-daily daclatasvir + once-daily sofosbuvir + low initial dose of ribavirin for 12 weeks (or daclatasvir + sofosbuvir for 24 weeks in ribavirin-ineligible cases)
  - Once-daily sofosbuvir/velpatasvir + ribavirin for 12 weeks (or sofosbuvir/velpatasvir for 24 weeks in ribavirin-ineligible cases)

- For cases with a history of treatment failure with a regimen containing sofosbuvir or an NS5A inhibitor, the following regimen is recommended:
  - Sofosbuvir/velpatasvir + ribavirin for 24 weeks.
USE OF RIBAVIRIN IN RIBAVIRIN-ELIGIBLE CASES WITH DECOMPENSATED CIRRHOSIS

- When used with ledipasvir/sofosbuvir or daclatasvir + sofosbuvir, the initial dose of ribavirin should be a total daily dose of 600 mg, in divided doses twice daily, increasing to a full weight-based regimen as tolerated (RBV-LD).

- For use with sofosbuvir/velpatasvir, AASLD indicates that a full weight-based ribavirin dose may be started in cases with CTP Class B decompensated cirrhosis, while the low initial dose (described in the above bullet) is used in cases with CTP Class C.

- Ribavirin dosage adjustments may be required for inmates with low GFR or hemoglobin levels.

CONTRAINDICATIONS FOR CTP CLASSES B AND C:

- Elbasvir/grazoprevir is contraindicated in decompensated cirrhosis with CTP scores ≥ 7 (CTP class B or C).

- Interferon-containing regimens are contraindicated in decompensated cirrhosis.

- The use of paritaprevir/ritonavir/ombitasvir/dasabuvir is contraindicated with severe hepatic impairment (CTP class C) and is not recommended in CTP class B.

- Simeprevir is not recommended for use in decompensated cirrhosis with CTP class B or C.

**TABLE 2: HCV TREATMENT RECOMMENDATIONS FOR DECOMPENSATED CIRRHOSIS**

<table>
<thead>
<tr>
<th>Treatment History</th>
<th>Genotype</th>
<th>1 or 4</th>
<th>2 or 3</th>
<th>5 or 6</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TN or TE with PEG-IFN + RBV (RBV eligible)</strong></td>
<td>LDV/SOF + RBV-LD: 12 wks</td>
<td>DCV + SOF + RBV-LD: 12 wks</td>
<td>LDV/SOF + RBV-LD: 12 wks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SOV/VEL + RBV*: 12 wks</td>
<td>SOV/VEL + RBV*: 12 wks</td>
<td>SOV/VEL + RBV*: 12 wks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DCV + SOF + RBV-LD: 12 wks</td>
<td>DCV + SOF: 24 wks</td>
<td>DCV + SOF: 24 wks</td>
<td></td>
</tr>
<tr>
<td><strong>TN or TE with PEG-IFN + RBV (RBV ineligible)</strong></td>
<td>LDV/SOF: 24 wks</td>
<td>DCV + SOF: 24 wks</td>
<td>LDV/SOF: 24 wks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SOV/VEL: 24 wks</td>
<td>SOV/VEL: 24 wks</td>
<td>SOV/VEL: 24 wks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DCV + SOF: 24 wks</td>
<td>SOV/VEL: 24 wks</td>
<td>SOV/VEL: 24 wks</td>
<td></td>
</tr>
<tr>
<td><strong>TE with SOF (RBV eligible)</strong></td>
<td>LDV/SOF + RBV-LD: 24 wks</td>
<td>SOF/VEL + RBV*: 24 wks</td>
<td>SOF/VEL + RBV*: 24 wks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SOV/VEL + RBV*: 24 wks</td>
<td>SOF/VEL + RBV*: 24 wks</td>
<td>SOF/VEL + RBV*: 24 wks</td>
<td></td>
</tr>
<tr>
<td><strong>TE with NS5A (RBV eligible)</strong></td>
<td>SOV/VEL + RBV*: 24 wks</td>
<td>SOF/VEL + RBV*: 24 wks</td>
<td>SOF/VEL + RBV*: 24 wks</td>
<td></td>
</tr>
</tbody>
</table>

**ABBREVIATIONS:** See [GLOSSARY](#).

* A full weight-based ribavirin dose may be started in cases with CTP Class B decompensated cirrhosis, while low initial dose is used in cases with CTP Class C.
LIVER TRANSPLANT RECIPIENTS

See TABLE 3 below for a summary of HCV treatment recommendations for liver transplant recipients.

HCV GENOTYPE 1, 4, 5, OR 6 IN LIVER TRANSPLANT RECIPIENTS:

Recommended regimens for HCV genotype 1, 4, 5, or 6 in liver transplant recipients with ongoing or recurrent HCV infection—either treatment-naïve or treatment-experienced—are determined by the absence or presence of cirrhosis in the allograft, as described below.

Alternative regimens are described in the AASLD guidance.

- **No cirrhosis in the allograft:**
  - Glecaprevir/pibrentasvir once daily for 12 weeks or
  - Ledipasvir/sofosbuvir once daily + weight-based ribavirin twice daily for 12 weeks

- **Compensated cirrhosis in the allograft:**
  - Ledipasvir/sofosbuvir once daily + weight-based ribavirin twice daily for 12 weeks

- **Decompensated cirrhosis in the allograft:**
  - Ledipasvir/sofosbuvir once daily + low initial dose ribavirin twice daily for 12 weeks

HCV GENOTYPE 2 OR 3 IN LIVER TRANSPLANT RECIPIENTS:

Recommended regimens for HCV genotype 2 or 3 in liver transplant recipients with ongoing HCV infection—either treatment-naïve or treatment-experienced—are determined by the absence or presence of cirrhosis in the allograft, as follows:

- **No cirrhosis in the allograft:**
  - Glecaprevir/pibrentasvir once daily for 12 weeks or
  - Ledipasvir/sofosbuvir once daily + weight-based ribavirin twice daily for 12 weeks
  - Ledipasvir/sofosbuvir once daily + low initial dose ribavirin twice daily for 12 weeks for treatment-naïve or treatment-experienced patient with decompensated cirrhosis.

- **Compensated cirrhosis in the allograft:**
  - Ledipasvir/sofosbuvir once daily + weight-based ribavirin twice daily for 12 weeks

- **Decompensated cirrhosis in the allograft:**
  - Ledipasvir/sofosbuvir once daily + low initial dose ribavirin twice daily for 12 weeks

TABLE 3: HCV TREATMENT RECOMMENDATIONS FOR HCV IN LIVER TRANSPLANT RECIPIENTS

<table>
<thead>
<tr>
<th>STAGE OF FIBROSIS IN ALLOGRAFT</th>
<th>GENOTYPE 1, 4, 5, OR 6</th>
<th>GENOTYPE 2 OR 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>No cirrhosis</td>
<td>GLE/PIB: 12 wks</td>
<td>GLE/PIB: 12 wks</td>
</tr>
<tr>
<td></td>
<td>LDV/SOF + RBV-WB: 12 wks</td>
<td>DCV + SOF + RBV-LD: 12 wks</td>
</tr>
<tr>
<td>Compensated cirrhosis</td>
<td>LDV/SOF + RBV-WB: 12 wks</td>
<td>DCV + SOF + RBV-LD: 12 wks</td>
</tr>
<tr>
<td>Decompensated cirrhosis</td>
<td>LDV/SOF + RBV-LD: 12 wks</td>
<td>DCV + SOF + RBV-LD: 12 wks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VEL/SOF + RBV*: 12 wks</td>
</tr>
</tbody>
</table>

ABBREVIATIONS: See GLOSSARY.
* A full weight-based ribavirin dose may be started in cases with CTP Class B decompensated cirrhosis, while low initial dose is used in cases with CTP Class C.

Refer to the following table for DAA drug interactions with calcineurin inhibitors (cyclosporine, tacrolimus):

https://www.hcvguidelines.org/unique-populations/post-liver-transplant (scroll to bottom of the page)
CHRONIC KIDNEY DISEASE (CKD)

HCV is independently associated with the development of chronic kidney disease (CKD). Published studies indicate that HCV is associated with 1) a higher risk of developing proteinuria and CKD; 2) a higher risk for progression to end-stage-liver-disease (ESLD); and 3) an increased risk of mortality for dialysis patients.

No dosage adjustment is required for any of the current DAAs when the GFR is ≥ 30 (CKD stages 1, 2, and 3). For cases being considered for renal transplantation, consultation with the transplant consultant is recommended regarding timing of HCV treatment relative to transplantation.

• For patients with GFR < 30 (CKD stages 4 and 5), and any HCV genotype—either with no cirrhosis or with compensated cirrhosis, and either treatment-naïve or treatment-experienced—the recommended DAA treatment regimens are as follows:
  
  ▶ Glecaprevir/pibrentasvir once daily for 8 to 16 weeks may be used for all genotypes.
    Duration of treatment is the same as for those without CKD. No dosage adjustment is required.
  
  ▶ Elbasvir/grazoprevir once daily for 12 weeks may be used ONLY for genotypes 1a, 1b, or 4. It appears NOT to be a good choice for most DAA-experienced cases. No dosage adjustment is required. NS5A resistance testing is not required when elbasvir/grazoprevir is used to treat genotype 1a with a GFR < 30.
    ➔ See discussion of elbasvir/grazoprevir in Section 6.

• Ribavirin doses must be decreased with GFRs ≤50. For GFRs 30–50, ribavirin is dosed 200 mg alternating every other day with 400 mg. For GFR <30, including hemodialysis, the ribavirin dose is 200 mg daily.

• For kidney transplant recipients with HCV genotype 1 or 4 with no cirrhosis or with compensated cirrhosis, either treatment-naïve or treatment-experienced, glecaprevir (300mg) / pibrentasvir (120mg) or ledipasvir (90mg) / sofosbuvir (400mg), once daily for 12 weeks are the preferred DAA regimens. No dosage adjustments are required.

• For kidney transplant recipients with HCV genotype 2, 3, 5, or 6 with no cirrhosis or with compensated cirrhosis, either treatment-naïve or treatment-experienced, glecaprevir (300mg) / pibrentasvir (120mg) is the preferred DAA regimen. No dosage adjustment is required.
PREGNANCY

Safety and efficacy data are limited regarding use of HCV DAAs during pregnancy. The current AASLD/IDSA guidance does NOT recommend treatment of HCV during pregnancy.

Ribavirin is contraindicated during pregnancy:

• Women of childbearing potential who are being considered for an HCV regimen that includes ribavirin should be counseled on the adverse fetal effects of ribavirin. They should be advised not to become pregnant during treatment with ribavirin and for six months after the treatment has ended. They should also be advised that the same risks apply if a male sex partner is being treated with ribavirin.

  ➔ A negative pregnancy test should be documented prior to starting treatment with ribavirin, monthly during treatment, and for six months after treatment.

• Men being treated with ribavirin should also be counseled on the adverse fetal effects of ribavirin. They should be advised not to cause pregnancy in their female sex partners during treatment with ribavirin and for six months after the treatment has ended.
REFERENCES


Note about the AASLD/IDSA website: To provide healthcare professionals with timely guidance as new therapies are available and integrated into HCV regimens, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), have developed a web-based process for the rapid formulation and dissemination of evidence-based, expert-developed recommendations for hepatitis C management.

Please refer to the AASLD/IDSA website for any updates since May 24, 2018.


# Glossary of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AASLD</td>
<td>American Association for the Study of Liver Diseases</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>ANA</td>
<td>antinuclear antibody</td>
</tr>
<tr>
<td>APRI</td>
<td>AST to Platelet Ratio Index</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CTP score</td>
<td>Child-Turcotte-Pugh score</td>
</tr>
<tr>
<td>DAA</td>
<td>direct acting antiviral medication</td>
</tr>
<tr>
<td>DCV</td>
<td>daclatasvir</td>
</tr>
<tr>
<td>DSV</td>
<td>dasabuvir</td>
</tr>
<tr>
<td>EGD</td>
<td>esophagogastroduodenoscopy</td>
</tr>
<tr>
<td>EBR</td>
<td>elbasvir</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>GLE</td>
<td>glecaprevir</td>
</tr>
<tr>
<td>GZR</td>
<td>grazoprevir</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HCC</td>
<td>hepatocellular carcinoma</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>HIV Ab or anti-HIV</td>
<td>HIV antibody</td>
</tr>
<tr>
<td>IDSA</td>
<td>Infectious Diseases Society of America</td>
</tr>
<tr>
<td>INR</td>
<td>International Normalization Ratio</td>
</tr>
<tr>
<td>LDV</td>
<td>ledipasvir</td>
</tr>
<tr>
<td>NASH</td>
<td>nonalcoholic steatohepatitis</td>
</tr>
<tr>
<td>OBV</td>
<td>ombitasvir</td>
</tr>
<tr>
<td>PTV</td>
<td>paritaprevir</td>
</tr>
<tr>
<td>PEG-IFN</td>
<td>pegylated interferon, peginterferon</td>
</tr>
<tr>
<td>PI</td>
<td>protease inhibitor</td>
</tr>
<tr>
<td>PIB</td>
<td>pibrentasivir</td>
</tr>
<tr>
<td>PrO</td>
<td>paritaprevir/ritonavir/ombitasvir</td>
</tr>
<tr>
<td>PrOD</td>
<td>paritaprevir/ritonavir/ombitasvir/dasabuvir</td>
</tr>
<tr>
<td>PT</td>
<td>prothrombin time</td>
</tr>
<tr>
<td>RAS</td>
<td>resistance-associated substitution</td>
</tr>
<tr>
<td>RBV</td>
<td>ribavirin</td>
</tr>
<tr>
<td>RBV-LD</td>
<td>ribavirin low initial dose</td>
</tr>
<tr>
<td>SOF</td>
<td>sofosbuvir</td>
</tr>
<tr>
<td>SMV</td>
<td>simprevir</td>
</tr>
<tr>
<td>SVR</td>
<td>sustained virologic response</td>
</tr>
<tr>
<td>TE</td>
<td>treatment-experienced</td>
</tr>
<tr>
<td>TN</td>
<td>treatment-naïve</td>
</tr>
<tr>
<td>TSH</td>
<td>thyroid stimulating hormone</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>VEL</td>
<td>velpatasvir</td>
</tr>
<tr>
<td>VOX</td>
<td>voxilaprevir</td>
</tr>
</tbody>
</table>
### APPENDIX 1. TREATMENT OPTIONS FOR HCV GENOTYPES 1, 4, 5, AND 6A,B,C

<table>
<thead>
<tr>
<th>Condition</th>
<th>Treatment Options by HCV GenotypeD</th>
<th>Genotypes 1a and 1bE,F,G</th>
<th>Genotype 4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NO CIRRHOSIS</td>
<td>COMPENSATED CIRRHOSIS</td>
<td>NO CIRRHOSIS</td>
</tr>
<tr>
<td>Treatment-Naive</td>
<td>▶ EB/GZR: 12 wks</td>
<td>▶ EB/GZR: 12 wks</td>
<td>▶ EB/GZR: 12 wks</td>
</tr>
<tr>
<td></td>
<td>▶ GLE/PIB: 8 wks</td>
<td>▶ GLE/PIB: 12 wks</td>
<td>▶ GLE/PIB: 12 wks</td>
</tr>
<tr>
<td></td>
<td>▶ LDV/SOF: 12 wks</td>
<td>▶ LDV/SOF: 12 wks</td>
<td>▶ LDV/SOF: 12 wks</td>
</tr>
<tr>
<td></td>
<td>▶ SOF/VEL: 12 wks</td>
<td>▶ SOF/VEL: 12 wks</td>
<td>▶ SOF/VEL: 12 wks</td>
</tr>
<tr>
<td>Treatment-Experienced w/ PEG-IFN + RBV</td>
<td>▶ EB/GZR: 12 wks</td>
<td>▶ EB/GZR: 12 wks</td>
<td>▶ EB/GZR: 12 wks</td>
</tr>
<tr>
<td></td>
<td>▶ GLE/PIB: 8 wks</td>
<td>▶ GLE/PIB: 12 wks</td>
<td>▶ GLE/PIB: 12 wks</td>
</tr>
<tr>
<td></td>
<td>▶ LDV/SOF: 12 wks</td>
<td>▶ LDV/SOF: 12 wks</td>
<td>▶ LDV/SOF: 12 wks</td>
</tr>
<tr>
<td></td>
<td>▶ SOF/VEL: 12 wks</td>
<td>▶ SOF/VEL: 12 wks</td>
<td>▶ SOF/VEL: 12 wks</td>
</tr>
<tr>
<td>Treatment-Experienced w/ PI + PEG-IFN + RBV</td>
<td>▶ GLE/PIB: 12 wks</td>
<td>▶ GLE/PIB: 12 wks</td>
<td>▶ GLE/PIB: 12 wks</td>
</tr>
<tr>
<td></td>
<td>▶ LDV/SOF: 12 wks</td>
<td>▶ LDV/SOF: 12 wks</td>
<td>▶ LDV/SOF: 12 wks</td>
</tr>
<tr>
<td></td>
<td>▶ SOF/VEL: 12 wks</td>
<td>▶ SOF/VEL: 12 wks</td>
<td>▶ SOF/VEL: 12 wks</td>
</tr>
<tr>
<td>Treatment-Experienced w/ SOF + RBV + PEG-IFN or SOF + PI +/− RBV</td>
<td>▶ GLE/PIB: 12 wks</td>
<td>▶ GLE/PIB: 12 wks</td>
<td>▶ GLE/PIB: 12 wks</td>
</tr>
<tr>
<td></td>
<td>(1a)</td>
<td>(1a)</td>
<td>(1a)</td>
</tr>
<tr>
<td></td>
<td>▶ SOF/VEL/VOX: 12 wks</td>
<td>▶ SOF/VEL/VOX: 12 wks</td>
<td>▶ SOF/VEL/VOX: 12 wks</td>
</tr>
<tr>
<td></td>
<td>(1b)</td>
<td>(1b)</td>
<td>(1b)</td>
</tr>
<tr>
<td></td>
<td>▶ SOF/VEL: 12 wks</td>
<td>▶ SOF/VEL: 12 wks</td>
<td>▶ SOF/VEL: 12 wks</td>
</tr>
<tr>
<td>Treatment-Experienced w/ NS5A inhibitor</td>
<td>▶ SOF/VEL/VOX: 12 wks</td>
<td>▶ SOF/VEL/VOX: 12 wks</td>
<td>▶ SOF/VEL/VOX: 12 wks</td>
</tr>
</tbody>
</table>

A. All regimens in this Appendix are identified as Recommended in the AASLD guidance. Alternative regimens may be appropriate in some cases, but are not included in this table. Some AASLD recommended regimens are not FDA-approved, but are based on available evidence.

B. Choice of regimen is determined by HCV genotype, treatment history, presence of compensated cirrhosis or no cirrhosis, and resistance-associated substitutions; it is also influenced by potential drug interactions and cost.

C. Recommendations in this table may not be appropriate in decompensated cirrhosis, chronic kidney disease with GFR < 30, liver or kidney transplant recipients. Refer to the specific sections in this guidance for treatment of HCV in these settings.

D. Genotypes 5 and 6, with compensated or no cirrhosis: GLE/PIB (no cirrhosis-8wks; cirrhosis-12 wks), LDV/SOF or SOF/VEL once daily are recommended for treatment-naïve patients or patients who previously failed treatment with PEG-IFN + RBV. Duration of GLE/PIB is 8 weeks in patients without cirrhosis; all other regimens are for 12 weeks. SOF/VEL/VOX once daily for 12 weeks is recommended for DAA-experienced patients with compensated or no cirrhosis.

E. NS5A resistance testing is recommended prior to treatment with EB/GZR for all genotype 1a cases, except those with GFR < 30 or with end stage renal disease. A regimen of EB/GZR alone is recommended only for cases with no RASs on NS5A resistance testing. If a RAS is present in genotype 1a, RBV is added to EB/GZR for a 16 week duration. Refer to the AASLD guideline on monitoring for specific substitutions associated with resistance.

NS5A resistance testing also may be considered for treatment-experienced genotype 1a cases with or without cirrhosis being considered for LDV/SOF: Resistance levels of 100-fold or less are required to use LDV/SOF in these situations.

F. EB/GZR alone is NOT to be used in genotype 1a with certain NSSA RASs and GFR ≥ 30. HCV virologic resistance testing is required prior to treatment with EB/GZR for all genotype 1a cases, except those with GFR < 30 or end stage renal disease. A regimen of EB/GZR alone is recommended only for cases with no RASs on NSSA resistance testing. If a RAS is present in genotype 1a, RBV is added to ELB/GZR for a 16-week duration. Refer to the AASLD guideline on monitoring for the specific substitutions associated with resistance.

G. An 8-week regimen with LDV/SOF is AASLD-recommended for treatment-naive genotype 1a with an HCV viral load <6 million IU/ml—but who are not black or HIV-coinfected, and who do not have cirrhosis.

**MEDICATIONS:**
- DCV = daclatasvir; EB/R/GZR = elbasivir/grazoprevir; GLE/PIB = glecaprevir/pibrentasvir (Mavyret™);
- LDV/SOF = ledipasvir/sofosbuvir (Harvoni®); PEG-IFN = pegylated interferon (peginterferon);
- PI = protease inhibitor (boceprevir, telaprevir, simeprevir); PrOD = paritaprevir/ritonavir/ombitasvir; P/O/O/D = paritaprevir/ritonavir/ombitasvir/dasabuvir (Viekira XR™); RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir; SOF/VEL = sofosbuvir/velpatasvir (Epclusa®); SOF/VEL/VOX = sofosbuvir/velpatasvir/voxlamprevir (Vosevi®)
### APPENDIX 2. TREATMENT OPTIONS FOR HCV GENOTYPES 2 AND 3 A,B,C

<table>
<thead>
<tr>
<th>CONDITION</th>
<th>GENOTYPE 2</th>
<th>GENOTYPE 3&lt;sup&gt;0&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NO CIRRHOSIS</td>
<td>COMPENSATED CIRRHOSIS</td>
</tr>
<tr>
<td>Treatment-Naive</td>
<td>GLE/PIB: 8 wks</td>
<td>GLE/PIB: 12 wks</td>
</tr>
<tr>
<td></td>
<td>SOF/VEL: 12 wks</td>
<td>SOF/VEL: 12 wks</td>
</tr>
<tr>
<td>Treatment-Experienced w/ PEG-IFN + RBV</td>
<td>GLE/PIB: 8 wks</td>
<td>GLE/PIB: 12 wks</td>
</tr>
<tr>
<td></td>
<td>SOF/VEL: 12 wks</td>
<td>SOF/VEL: 12 wks</td>
</tr>
<tr>
<td>Treatment-Experienced w/ SOF + RBV +/- PEG-IFN</td>
<td>GLE/PIB: 12 wks</td>
<td>GLE/PIB: 12 wks</td>
</tr>
<tr>
<td></td>
<td>SOF/VEL: 12 wks</td>
<td>SOF/VEL: 12 wks</td>
</tr>
<tr>
<td>Treatment Experienced w/ SOF + NS5A inhibitor</td>
<td>SOF/VEL/VOX: 12 wks</td>
<td>SOF/VEL/VOX: 12 wks</td>
</tr>
</tbody>
</table>

**A.** All regimens in this Appendix are identified as *RECOMMENDED* in the AASLD guidance. Alternative regimens may be appropriate in some cases, but are not included in this table. Some AASLD recommended regimens are not FDA-approved, but are based on available evidence.

**B.** *Choice of regimen* is determined by HCV genotype, treatment history, presence of compensated cirrhosis or no cirrhosis, and resistance-associated substitutions; it is also influenced by potential drug interactions and cost.

**C.** Recommendations in this table may not be appropriate in cases of decompensated cirrhosis, chronic kidney disease with GFR <30, or liver or kidney transplant recipients. Refer to the specific sections in this guidance for treatment of HCV in these settings.

**D.** *NS5A resistance testing is recommended for genotype 3 cases*, either treatment-naive with cirrhosis or treatment-experienced with PEG-IFN+RBV and no cirrhosis, that are being considered for DCV + or SOF. If the Y93H RAS is present, the addition of weight-based RBV to a regimen of either is recommended or a different DAA regimen should be selected, if appropriate.

**MEDIcATIONS:**
- *DCV* = daclatasvir; *EBR/GZR* = elbasvir/grazoprevir; *GLE/PIB* = glecaprevir/pibrentasvir (Mavyret™);
- *LDV/SOF* = ledipasvir/sofosbuvir (Harvoni®); *PEG-IFN* = pegylated interferon (peginterferon);
- *PI* = protease inhibitor (boceprevir, telaprevir, simeprevir); *PrO* = paritaprevir/ritonavir/ombitasvir;
- *PrOd* = paritaprevir/ritonavir/ombitasvir/dasabuvir (Viekira XR™); *RBV* = ribavirin; *SMV* = simprevir; *SOF* = sofosbuvir;
- *SOF/VEL* = sofosbuvir/velpatasvir (Epclusa®); *SOF/VEL/VOX* = sofosbuvir/velpatasvir/voxilaprevir (Vosevi®)
### APPENDIX 3. HEPATITIS C TREATMENT MONITORING SCHEDULE

<table>
<thead>
<tr>
<th>Evaluation1</th>
<th>Baseline (anti-HCV positive)</th>
<th>Pretreatment (Within 90 days of Tx)</th>
<th>On-Treatment Monitoring (by week of treatment)2</th>
<th>12 wks post-treatment</th>
<th>6–12 mos post-treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinician evaluation</td>
<td>X X X X X X X X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV Ab, HBV Serology2, Anti-HAV (IgG)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prothrombin Time / INR</td>
<td>X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC</td>
<td>X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum creatinine + eGFR</td>
<td>X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT, AST, bilirubin, alkaline phosphatase, albumin</td>
<td>X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APRI &amp; CTP scores5</td>
<td>X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV RNA, quantitative 6</td>
<td>X X</td>
<td></td>
<td>See footnote #6.</td>
<td>X X</td>
<td></td>
</tr>
<tr>
<td>HCV genotype</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assess for drug-drug interactions &amp; adherence</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review incident report history for high risk behavior (alcohol / drug possession / use; tattooing)</td>
<td>X</td>
<td></td>
<td>If indicated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine pregnancy test 7</td>
<td>X X X X X X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Conduct further diagnostic evaluations as clinically warranted to identify other potential causes of the patient’s liver disease such as hemochromatosis, Wilson’s disease, or autoimmune hepatitis (e.g., serum iron, serum copper, ANA/ESR). If any of these conditions are diagnosed or strongly suspected, a pre-treatment liver biopsy should be considered.

2. More frequent monitoring may be required if clinically indicated.

3. **Recommended baseline testing for hepatitis B status includes HBsAg, anti-HBs, and anti-HBe.** If either HBsAg or anti-HBe is positive, obtain an HBV DNA viral load. If criteria for treatment of HBV are met, initiating antiviral therapy for HBV is recommended prior to or at the same time as HCV treatment. If criteria for treatment of chronic HBV infection are not met, monthly HBV DNA viral loads are recommended during treatment for HCV.

4. **More frequent monitoring of ALT is necessary in certain situations:** 1) **Regimens containing elbasvir/grazoprevir:** An ALT should be drawn at 4 weeks and again at 8 weeks, and as clinically indicated. For 16-week regimens, an ALT should also be drawn at 12 weeks; 2) **Patients with compensated cirrhosis** who are treated with paritaprevir/ritonavir/ombitasvir, with or without dasabuvir, require more frequent monitoring of ALT; 3) **Increases in the ALT should prompt more frequent monitoring or early discontinuation.** Asymptomatic ALT increases of less than tenfold should be monitored approximately every 2 weeks. Early discontinuation of HCV treatment is recommended if ALT increases by tenfold—or if less than tenfold, but accompanied by symptoms such as weakness, anorexia, nausea, vomiting, or change in stool color, or signs including elevations in conjugated bilirubin, alkaline phosphatase, and INR, related to hepatic dysfunction.

5. A CTP score is calculated only for cases with known or suspected cirrhosis.

6. For treatment regimens recommended in this document, the routine schedule of HCV RNA testing includes baseline testing, after 4 weeks on treatment, and 12 weeks after completion of therapy. BOP recommends pretreatment testing of HCV RNA if the most recent test was performed more than 1 year ago. If the quantitative HCV viral load is detectable after 4 weeks of treatment, it should be repeated 2 weeks later. An HCV RNA is no longer necessary at the end of treatment unless undetectable levels were not achieved during treatment. If HCV RNA is undetectable 12 weeks after treatment, BOP recommends repeat testing 6 to 12 months after completion of treatment.

7. On- and post-treatment monitoring for pregnancy is recommended only for RBV-containing regimens. A pre-treatment pregnancy test is recommended for all regimens. **RIBAVIRIN-CONTAINING REGIMENS:** A pretreatment ECG is recommended for inmates with preexisting coronary heart disease. A CBC should be obtained two and four weeks after starting treatment, every four weeks while on treatment, and more frequently as clinically indicated.
### APPENDIX 4. MANAGEMENT OF HEMATOLOGIC CHANGES

**Note:** For patients prescribed a direct-acting antiviral (DAA) for HCV infection (e.g., sofosbuvir or simeprevir), if ribavirin must be discontinued due to hematologic changes, the DAA also may need to be discontinued. Consultation with an experienced clinician is recommended.

#### HEMOGLOBIN (Hgb)

<table>
<thead>
<tr>
<th>Value</th>
<th>Peginterferon/Ribavirin Adjustment and Supportive Treatment</th>
</tr>
</thead>
</table>
| 10–11 g/dL | - Peginterferon → No change.  
- Ribavirin ☐  
  ▶ If no or minimal symptoms, then no dose modification.  
  ▶ If symptomatic, decrease ribavirin by 200 mg/day. |
| 8.5–10 g/dL | - Peginterferon ☐  
  ▶ Peginterferon alfa 2a (Pegasys) → No change.  
  ▶ Peginterferon alfa 2b (PEG-Intron) → Reduce 50% (see note below).  
- Ribavirin ☐  
  ▶ 1 to 600 mg daily (200 mg AM & 400 mg PM) |
| <8.5 g/dL  | - Peginterferon ☐  
  ▶ Peginterferon alfa 2a (Pegasys) → No change.  
  ▶ Peginterferon alfa 2b (PEG-Intron) → Discontinue until resolved.  
- Ribavirin ☐  
  ▶ Discontinue until resolved. |

**Candidates for Erythropoietin:** Rule out other causes of anemia. If anemia persists at 2 weeks after reducing ribavirin—and there is no hypertension—then consider erythropoietin, especially if the patient demonstrates a virologic response. Erythropoietin should be considered primarily for patients who are cirrhotic, post-transplant, HIV/HCV coinfected, or treated with a DAA.

**Dosage:** Epoetin alfa 40,000 units subcutaneously weekly  
**Goal:** Hemoglobin 12 g/dL  
**Note:** If hemoglobin is <12 g/dL for more than 4 weeks at the reduced/adjusted dose, then discontinue ribavirin.

#### ABSOLUTE NEUTROPHIL COUNT (ANC)

<table>
<thead>
<tr>
<th>Value</th>
<th>Peginterferon/Ribavirin Adjustment and Supportive Treatment</th>
</tr>
</thead>
</table>
| <750    | - Peginterferon ☐  
  ▶ Peginterferon alfa 2a (Pegasys) → Reduce dose to 135 microgram/week (75% dose).  
  ▶ Peginterferon alfa 2b (PEG-Intron) → Reduce to a 50% dose (see note below).  
- Ribavirin ☐  
  ▶ No change. |
| < 500   | - Peginterferon & Ribavirin → Discontinue both until resolved. |

**Granulocyte Colony Stimulating Factor (G-CSF):** If the patient is responding to treatment and neutropenia persists despite reduced peginterferon dose, consider G-CSF (in consultation with an expert) for patients who are cirrhotic, post-transplant, HIV/HCV coinfected, or treated with a DAA.

**Dosage:** Filgrastim 300 microgram subcutaneous daily or less frequently  
**Goal:** ANC >1500

#### PLATELETS

<table>
<thead>
<tr>
<th>Value</th>
<th>Peginterferon/Ribavirin Adjustment and Supportive Treatment</th>
</tr>
</thead>
</table>
| <50,000  | - Peginterferon ☐  
  ▶ Peginterferon alfa 2a (Pegasys) → Reduce dosage to 90 micrograms/week (50% dose) (see note below).  
  ▶ Peginterferon alfa 2b (PEG-Intron) → Discontinue until resolved.  
- Ribavirin ☐  
  ▶ If on PEG-Intron, then discontinue ribavirin. |
| <30,000  | - Peginterferon → Discontinue until resolved.  
- Ribavirin → Discontinue until resolved. |

**Note:** While the manufacturer of peginterferon recommends reducing dose to 50%, recent data suggest that lowering the dose to this extent may significantly reduce the likelihood of achieving an SVR. Some experts recommend a 25% dose reduction with close monitoring of hematologic parameters.

---

*Note: The values and treatments listed are based on the clinical guidance provided in the document. Consultation with an experienced clinician is recommended for specific patient cases.*
APPENDIX 5. RESOURCES—PREVENTION AND TREATMENT OF VIRAL HEPATITIS

HEALTH CARE PROFESSIONALS

- American Association for the Study of Liver Diseases and Infectious Disease Society of America Hepatitis C Guidance  
  http://www.hcvguidelines.org

- Centers for Disease Control and Prevention  
  National Center for Infectious Diseases—Hepatitis Branch  
  http://www.cdc.gov/ncidod/diseases/hepatitis/

- MELD Score Calculator  

- National Institutes of Health  
  National Institute of Diabetes and Digestive and Kidney Diseases  
  http://www.niddk.nih.gov

- National Clinicians’ Post-Exposure Prophylaxis PEPLine: (888) 448-4911  
  http://www.nccc.ucsf.edu/

- U.S. Department of Veterans Affairs National Hepatitis C Program  
  http://www.hepatitis.va.gov/

PATIENT EDUCATION

- American Liver Foundation (ALF)  
  http://www.liverfoundation.org

- Centers for Disease Control and Prevention (CDC)  
  http://www.cdc.gov/ldu/hepatitis/index.htm

- Hepatitis Foundation International (HFI)  
  http://www.hepfi.org

- The National Digestive Diseases Information Clearinghouse (NDDIC)  

- U.S. Department of Veterans Affairs National Hepatitis C Program—For Veterans and the Public  
APPENDIX 6. HEPATITIS C TREATMENT ALGORITHM/NONFORMULARY REQUEST WORKSHEET

The BOP *Hepatitis C Treatment Algorithm/Nonformulary Request Worksheet* is available on the next page.
**Hepatitis C Treatment Algorithm/Nonformulary Request Worksheet**

**U.S. DEPARTMENT OF JUSTICE**  
**FEDERAL BUREAU OF PRISONS**

### Inmate Information

<table>
<thead>
<tr>
<th>Inmate Name:</th>
<th>Projected Release Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Register Number:</td>
<td>Weight (lb.): (within 90 days of request)</td>
</tr>
</tbody>
</table>

### APRI Score and Date

<table>
<thead>
<tr>
<th>APRI Score:</th>
<th>APRI Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \text{APRI} = \left( \frac{[\text{AST/ULN}\ \text{AST}]}{\text{Plt}} \right) \times 100 )</td>
<td></td>
</tr>
</tbody>
</table>

### CTP Score (if cirrhotic)

<table>
<thead>
<tr>
<th>CTP Points (circle):</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

#### Albumin (g/dL)

- \( >3.5 \)
- \( 2.8-3.5 \)
- \( <2.8 \)

#### Bilirubin (mg/dL)

- \( <2 \)
- \( 2-3 \)
- \( >3 \)

#### INR

- \( <1.7 \)
- \( 1.7-2.3 \)
- \( >2.3 \)

### Encephalopathy

- None
- Grade 1-2
- Grade 3-4

### Ascites

- None
- Diuretic responsive
- Diuretic refractory

### Liver Biopsy Result (amount of fibrosis)

- Date Performed: ☐ Not Performed

#### Liver Biopsy

- Portal
- Periportal
- Bridging
- Cirrhosis
- None

#### Note:

For regimens with elbasvir/grazoprevir in the treatment of HCV genotype 1a, an HCV NSSA virologic resistance test is required.

### Prior Antiviral Treatment for HCV

- ☐ No
- ☐ Yes

If yes, answer the following:

#### Drug Names and Dosages:

- Start Date: Stop Date: Reason stopped:

#### Prior Treatment Response

- ☐ SVR
- ☐ Relaper
- ☐ Partial Responder
- ☐ Null Responder

### Requested Treatment Regimen (check all that apply):

- Daclatasvir
- Sofosbuvir
- Simeprevir
- Ledipasvir/sofosbuvir (Harvoni®)
- Paritaprevir/ritonavir/ombitasvir/dasabuvir (Viekira®)
- Sofosbuvir/velpatasvir (Epclusa®)
- Ribavirin

### Medical Clearance:

- ☐ Sentenced inmate with sufficient time remaining on sentence to complete a course of treatment prior to halfway house (RRC), home confinement, or GCT/Full Term release.
- ☐ No sanctions for drug or alcohol/intoxicant possession/use, or tattooing within previous 1 year.
- ☐ No documented non-adherence to prior therapy, failure to complete pretreatment evaluation process, or unwillingness to commit or consent to HCV treatment.
- ☐ No contraindications or drug interactions with requested treatment regimen.
- ☐ No uncontrolled or unstable medical or mental health conditions.
- ☐ No current pregnancy.

### Required Documentation – include copies of the following with this request:

- CBC, serum creatinine and eGFR, liver panel, INR (dated within 90 days of request).
- HCV RNA viral load (reported as IU/ml) and genotype (dated within 90 days of request).
- HIV Ab – if positive, include CD4 and HIV viral load (dated within 90 days of request) and current antiretroviral medication regimen.
- Hepatitis B serology (sAb, sAg, and cAb) – if sAg reactive, include eAg, eAb, and HBV DNA viral load.
- Liver biopsy report (if performed, but not required unless clinically indicated).
- If cirrhosis or APRI \( \geq 2 \) (defined by pathology or clinical findings), include abdominal US or CT.
- Pregnancy test if woman with child-bearing potential (dated within 90 days of request).

### PROCEDURE FOR SUBMITTING HCV TREATMENT REQUEST

- Generate a BEMR non-formulary request (NFR) for Hepatitis C Treatment Algorithm.
- Include all information and attach all required documentation from above.
- May scan and attach Hepatitis C Treatment Algorithm Nonformulary Request Worksheet to NFR.